Skip to earnings analysis
← Back to feed
DOC FY2026 Q2 IMPROVING

Physicians Realty Trust earnings call

Aug 05, 2026 · 10:00 ET Andrew JohnsKelvin MurphyScott Bohn
Buzzberg read

Life science occupancy inflecting with strong leasing and LOI pipeline

HealthPeak reported strong Q2 2026 results with a raised full-year FFO guidance, driven by improving life science fundamentals and robust outpatient medical performance. The company completed a $1 billion recapitalization JV with Brookfield, substantially strengthening its balance sheet and funding future growth. Raised FY2026 FFO guidance to $1.73-$1.77 per share, up 2 cents, citing improved same-store NOI outlook.

Buzzberg read Life science occupancy inflecting with strong leasing and LOI pipeline HealthPeak reported strong Q2 2026 results with a raised full-year FFO guidance, driven by improving life science fundamentals and robust outpatient medical performance. The company completed a $1 billion recapitalization JV with Brookfield, substantially strengthening its balance sheet and funding future growth. Raised FY2026 FFO guidance to $1.73-$1.77 per share, up 2 cents, citing improved same-store NOI outlook. Read full analysisCollapse analysis

HealthPeak reported strong Q2 2026 results with a raised full-year FFO guidance, driven by improving life science fundamentals and robust outpatient medical performance. The company completed a $1 billion recapitalization JV with Brookfield, substantially strengthening its balance sheet and funding future growth. Raised FY2026 FFO guidance to $1.73-$1.77 per share, up 2 cents, citing improved same-store NOI outlook.

  • Completed Brookfield JV for a 5.6M sq ft outpatient portfolio, raising $1B in cash, with call rights to buy back the stake at a 6.5% unlevered IRR.
  • Lab total occupancy reached 78.5%, up 140 bps YTD, with strong leasing at Torrey Pines (97% leased including LOIs).
  • Outpatient medical continues to show strength with +5% cash releasing spreads and low TI requirements.
Revenue $0.7716B reported
EPS $0.08 reported
Gross margin 56.83% reported
Op margin 16.18% reported

What changed this quarter

01
Demand

Life science occupancy inflecting with strong leasing and LOI pipeline

Demand in outpatient medical remains strong with cash releasing spreads of 5% and a leasing pipeline expected to accelerate internal growth in 2027. Life science is improving with strong leasing volumes, a 480,000 square foot LOI pipeline, and significant occupancy gains…

02
Demand

Torrey Pines leased percentage surged from 65% to 97%

Demand in outpatient medical remains strong with cash releasing spreads of 5% and a leasing pipeline expected to accelerate internal growth in 2027. Life science is improving with strong leasing volumes, a 480,000 square foot LOI pipeline, and significant occupancy gains…

03
Partnerships

Two major institutional JVs validate outpatient medical strategy

Completed Brookfield JV for a 5.6M sq ft outpatient portfolio, raising $1B in cash, with call rights to buy back the stake at a 6.5% unlevered IRR.

04
Occupancy

Lab portfolio occupancy up 140 bps since year end

Lab total occupancy reached 78.5%, up 140 bps YTD, with strong leasing at Torrey Pines (97% leased including LOIs).

Demand & capex

Demand

Bookings & conversion

Demand in outpatient medical remains strong with cash releasing spreads of 5% and a leasing pipeline expected to accelerate internal growth in 2027. Life science is improving with strong leasing volumes, a 480,000 square foot LOI pipeline, and significant occupancy gains, particularly in Torrey Pines. Senior housing is seeing strong demand with 260 basis points of occupancy growth and a doubling o

Capex

Investment and capacity

Management noted that capital costs to capture occupancy are generally modest, with around 10% for renewals and 20-25% for new leasing, except for redevelopment assets which may require elevated capital. They emphasized their portfolio advantage in avoiding shell build-outs and keeping capital deployment low.

Tone · Confident

Management expressed confidence in the recovery of life science and the strength of outpatient medical and senior housing, highlighted by successful strategic partnerships and improved balance sheet.

Supply-chain alpha

A1

HealthPeak's lab pipeline is concentrated on smaller tenants (25-75k sq ft) and is seeing a shift from development to acquisition, with early signs of distressed asset opportunities.

“From a size perspective, we have seen more in that 25 to 75,000 square foot range, both in the executions as well as the LOI and pipeline bucket.”
Scott Bohn
A2

Torrey Pines submarket leased percentage increased to 97% from ~65% at year-end 2025, indicating severe supply constraint and strong pricing power in core life science clusters.

“When accounting for executed leases and LOIs, our leased percentage in the submarket increases to 97% from approximately 65% at year-end 2025.”
Kelvin Murphy

Forward guidance

ImprovingGuidance tone · was IN LINE last Q
Forward guidance
MetricPeriodRangeMidpointStatus
EPSFY2026$1.73–$1.77$1.75RAISED
UnitsTOTAL_OCCUPANCYFY202679%–79.5%79.25%GUIDED

Company read-throughs

+2.3%
since call
$168.58$172.45
Customers

Deep relationship with Northside Hospital continues to yield high-quality, pre-leased development projects, underpinning HealthPeak's outpatient growth.

“We're funding highly pre-leased outpatient development projects sourced directly through our relationships, such as the project in Atlanta that we announced last evening.”
Scott Brinker
+0.1%
since call
$44.68$44.73
Partners

Brookfield's significant capital deployment into outpatient medical through HealthPeak validates the asset class and provides a scalable JV framework for future growth.

“We're pleased to complete this strategic partnership as the proceeds raised exceed our capital recycling target for the year in a single transaction.”
Scott Brinker
+7.0%
since call
$136.88$146.41
Partners

Blackstone is gaining exposure to outpatient medical via HealthPeak's platform, which could lead to further capital deployment and bolster HealthPeak's AUM and fee income.

“Neither Blackstone nor Brookfield had any meaningful prior exposure to the outpatient medical sector. Both joint ventures allow us to maintain control of strategic buildings and tenant relationships”
Scott Brinker
-0.3%
since call
$48.31$48.16
-7.6%
since call
$39.23$36.24
Supply chainSupply-chain alpha

HealthPeak's lab pipeline is concentrated on smaller tenants (25-75k sq ft) and is seeing a shift from development to acquisition, with early signs of distressed asset opportunities. — Indicates a more normalized, granular leasing market, and signals that larger, capital-intensive CRE players with more distressed assets may face increasing competition from incumbents with strong balance sheets.

-0.3%
since call
$48.31$48.16
Supply chainSupply-chain alpha

Torrey Pines submarket leased percentage increased to 97% from ~65% at year-end 2025, indicating severe supply constraint and strong pricing power in core life science clusters.